secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001193125-25-211462
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec Biopharma FY2025 net loss $37.9M ($1.05/sh); BB-301 DSMB clears Cohort 2 enrollment
--------------------------------------------------------------------------------

- Net loss $37.9M ($1.05/share) vs $22.4M ($1.22/share) in FY2024; total expenses $41.8M (up 86%).
- R&D expense $18.3M (up 17%) on BB-301 clinical development; G&A $23.4M (up 235%) driven by stock-based comp $14.5M.
- Cash and equivalents $97.7M (up from $50.9M) after equity offerings.
- DSMB recommended continuation; Cohort 2 enrollment and interim Cohort 1 data both expected Q4 2025.
- BB-301 Phase 1b/2a for OPMD with dysphagia; no revenue reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525211462/0001193125-25-211462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312525211462/bntc-20250922.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-211462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer